Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Completed · Phase 2

Conditions studied: Recurrent Glioblastoma

In brief

This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.

Key facts

Study ID

NCT03034135

Run by

Cantex Pharmaceuticals

People needed

23

Starts

2017-03-09

Expected to finish

2018-07-10

Last updated by the study team

2021-09-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed GBM (WHO grade IV).
• The subject must have completed RT with concurrent TMZ at least 12 weeks prior to the planned start of treatment on this study UNLESS there is pathological verification of recurrent tumor and at least 4 weeks have elapsed since the end of RT with concurrent TMZ.
• Experienced first unequivocal progression of tumor by magnetic resonance imaging (MRI) [as assessed via Radiologic Assessment in Neuro-Oncology (RANO) criteria within 3 months from the last dose of TMZ.
• Karnofsky performance status (KPS) of at least 60%.
• Willing to remain abstinent from consuming alcohol.
• Recovered from the toxic effects of prior therapy to < grade 2 toxicity per NCI CTCAE prior to study registration (except lymphopenia).
• Meets laboratory criteria for the following parameters: ANC, platelets, hemoglobin, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, BUN and creatinine.
• 11. Females of childbearing potential must be willing to use an acceptable method of birth control (i.e., intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.

You may not qualify if…

• Radiographic evidence of leptomeningeal dissemination, gliomatosis cerebri, infratentorial tumor, or disease at sites remote from the supratentorial brain.
• Enrolled in another clinical trial testing a novel therapy or drug within the past 4 weeks.
• Received more than one course of radiation therapy or more than a total dose of 75 Gy.
• History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.
• Treatment with the following medications are contraindicated with DSF: metronidazole, isoniazid, dronabinol, carbocisteine, lopinavir, paraldehyde, ritonavir, sertraline, tindazole, tizanidine, atazanavir.
• Fever within 3 days prior to study enrollment.
• Active or severe hepatic or renal disease.
• Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE
• History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to glioblastoma, corticosteroid, or anti-epileptic medications.
• History of Wilson's disease.
• History of hemochromatosis.
• Pregnant or breastfeeding.

Where it is running

• Beaumont Hospital — Royal Oak, Michigan, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• John Theurer Cancer Center — Hackensack, New Jersey, United States
• Lenox Hill Hospital — New York, New York, United States
• University of Cincinnati — Cincinnati, Ohio, United States
• Vanderbilt Ingram Cancer Center — Nashville, Tennessee, United States
• Baylor University Medical Center — Dallas, Texas, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.